Rhone-Poulenc Rorer Rilutek (riluzole) for ALS approved Dec. 12, five-and-a-half months after NDA submission.
RPR's RILUTEK FOR ALS WILL BE AVAILABLE WITHIN SIX WEEKS following FDA approval of the first treatment for patients with amyotrophic lateral sclerosis (Lou Gehrig's disease) on Dec. 12. Rhone-Poulenc Rorer said its "number one goal is to make the drug available to ALS patients as quickly as possible." Rilutek will be available within six weeks as a 50 mg tablet to be administered twice daily. The company will officially launch the product Jan. 10 when it will discuss availability and patient support services.
You may also be interested in...
The US FDA is set for two high-profile advisory committee meetings on potential ALS treatments before the end of 2022. Whatever the outcome, they will fit a pattern: when it comes to ALS treatments, there is very little about the regulatory process that feels routine.
Biogen and Eisai's surprise decision to advance Alzheimer’s antibody despite mixed clinical results could follow a similar path as pioneering neurodegenerative therapies Xenazine and Rilutek, or more recent Parkinson’s drug Nourianz – or could end with suspended development, like Kyndrisa.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011